[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Relugolix.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sulpiride.]
[L02BA01, tamoxifen, The serum concentration of Relugolix can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Relugolix.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Relugolix.]
[B01AE07, dabigatran etexilate, The serum concentration of Relugolix can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Relugolix can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Relugolix.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Relugolix.]
[L04AX02, thalidomide, The metabolism of Relugolix can be increased when combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Relugolix.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Relugolix.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Relugolix.]
[N06AX05, trazodone, The serum concentration of Relugolix can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Relugolix can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Relugolix can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The metabolism of Relugolix can be decreased when combined with Triazolam.]
[R03BA07, mometasone, The metabolism of Relugolix can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Relugolix.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Relugolix.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Relugolix.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Relugolix.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Relugolix.]
[J01FA08, troleandomycin, The metabolism of Relugolix can be decreased when combined with Troleandomycin.]
[L01EX04, vandetanib, The serum concentration of Relugolix can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Relugolix can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Relugolix can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Relugolix can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Relugolix.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Relugolix.]
[B01AF01, rivaroxaban, The serum concentration of Relugolix can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Relugolix.]
[B01AC24, ticagrelor, The serum concentration of Relugolix can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Relugolix can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Relugolix can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Relugolix.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Relugolix.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Relugolix can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Relugolix can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Relugolix.]
[L01ED01, crizotinib, The serum concentration of Relugolix can be increased when it is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Relugolix.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The metabolism of Relugolix can be decreased when combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Relugolix.]
[J02AC03, voriconazole, The metabolism of Relugolix can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Relugolix.]
[R07AX02, ivacaftor, The serum concentration of Relugolix can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Relugolix can be increased when combined with Prednylidene.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Relugolix.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Relugolix.]
[G04BD12, mirabegron, The serum concentration of Relugolix can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Relugolix can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Relugolix can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Relugolix can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Relugolix can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Relugolix.]
[L01EX05, regorafenib, The serum concentration of Relugolix can be increased when it is combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Relugolix can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Relugolix.]
[C08CA13, lercanidipine, The metabolism of Relugolix can be decreased when combined with Lercanidipine.]
[N03AX22, perampanel, The metabolism of Relugolix can be decreased when combined with Perampanel.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Relugolix.]
[G04BE03, sildenafil, The serum concentration of Relugolix can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Relugolix can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Relugolix can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Relugolix can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Bencyclane.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Relugolix.]
[A10BK02, canagliflozin, The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Relugolix can be increased when it is combined with Tegaserod.]
[L04AA18, everolimus, The serum concentration of Relugolix can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Relugolix.]
[L01EC02, dabrafenib, The serum concentration of Relugolix can be decreased when it is combined with Dabrafenib.]
[L01EB03, afatinib, The serum concentration of Relugolix can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Relugolix can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Bepridil.]
[C02KX05, riociguat, The serum concentration of Relugolix can be increased when it is combined with Riociguat.]
[L01EL01, ibrutinib, The metabolism of Relugolix can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Relugolix can be decreased when combined with Vortioxetine.]
[J05AP05, simeprevir, The serum concentration of Relugolix can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Relugolix can be increased when it is combined with Sofosbuvir.]
[A16AA07, metreleptin, The metabolism of Relugolix can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Relugolix can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Relugolix can be increased when combined with Betamethasone.]
[L04AC11, siltuximab, The metabolism of Relugolix can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Relugolix.]
[B01AC26, vorapaxar, The serum concentration of Relugolix can be increased when it is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Relugolix.]
[L01XH04, belinostat, The serum concentration of Relugolix can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Relugolix can be increased when it is combined with Idelalisib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Relugolix.]
[N05CM19, suvorexant, The serum concentration of Relugolix can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Relugolix can be increased when it is combined with Eliglustat.]
[L01EX09, nintedanib, The serum concentration of Relugolix can be increased when it is combined with Nintedanib.]
[J05AP09, dasabuvir, The serum concentration of Relugolix can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Relugolix.]
[B01AF03, edoxaban, The serum concentration of Relugolix can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Relugolix.]
[L04AC10, secukinumab, The metabolism of Relugolix can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Relugolix can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Relugolix can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Relugolix.]
[J05AP07, daclatasvir, The serum concentration of Relugolix can be increased when it is combined with Daclatasvir.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Relugolix can be increased when it is combined with Asunaprevir.]
[A04AD14, rolapitant, The serum concentration of Relugolix can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Relugolix can be increased when it is combined with Flibanserin.]
[J02AC05, isavuconazole, The serum concentration of Relugolix can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Relugolix.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Relugolix.]
[B01AC27, selexipag, The serum concentration of Relugolix can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Relugolix.]
[J05AP10, elbasvir, The serum concentration of Relugolix can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Relugolix can be increased when it is combined with Grazoprevir.]
[L01XX52, venetoclax, The serum concentration of Relugolix can be increased when it is combined with Venetoclax.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Relugolix.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Relugolix.]
[N07BC01, buprenorphine, The metabolism of Relugolix can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Relugolix.]
[N05BE01, buspirone, The metabolism of Relugolix can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The serum concentration of Relugolix can be increased when it is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Relugolix.]
[S01GX07, azelastine, The metabolism of Relugolix can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Relugolix can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Relugolix can be decreased when combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Relugolix.]
[J05AE09, tipranavir, The serum concentration of Relugolix can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Relugolix.]
[L04AB02, infliximab, The metabolism of Relugolix can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of Relugolix can be decreased when it is combined with Midostaurin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Relugolix.]
[L01XX59, enasidenib, The serum concentration of Relugolix can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Relugolix can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Relugolix.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Relugolix.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Relugolix.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Relugolix.]
[C07AB07, bisoprolol, The serum concentration of Relugolix can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Relugolix can be decreased when combined with Efavirenz.]
[R03BA02, budesonide, The metabolism of Relugolix can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Relugolix can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Relugolix can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, The serum concentration of Relugolix can be increased when it is combined with Ertugliflozin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Relugolix.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Relugolix can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Relugolix can be decreased when it is combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Carbinoxamine.]
[C07AG02, carvedilol, The serum concentration of Relugolix can be increased when it is combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Relugolix can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Relugolix.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Relugolix.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Relugolix.]
[H01CC03, elagolix, The serum concentration of Relugolix can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Relugolix can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The serum concentration of Relugolix can be increased when it is combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Relugolix.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Relugolix.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Relugolix.]
[L01EB07, dacomitinib, The serum concentration of Relugolix can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Relugolix can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Relugolix.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Relugolix.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Relugolix.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Relugolix.]
[L01ED05, lorlatinib, The serum concentration of Relugolix can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Relugolix can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Relugolix.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Relugolix.]
[L01XJ03, glasdegib, The serum concentration of Relugolix can be increased when it is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Relugolix.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Triclabendazole.]
[J01FA09, clarithromycin, The serum concentration of Relugolix can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Relugolix can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Relugolix can be increased when it is combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Relugolix can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Relugolix can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Relugolix can be increased when combined with Cortivazol.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Relugolix.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cicletanine.]
[L01EJ02, fedratinib, The serum concentration of Relugolix can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Relugolix can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Relugolix can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Lefamulin can be increased when it is combined with Relugolix.]
[N04CX01, istradefylline, The serum concentration of Relugolix can be increased when it is combined with Istradefylline.]
[J01XX09, daptomycin, The serum concentration of Relugolix can be increased when it is combined with Daptomycin.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Relugolix.]
[N02CC08, lasmiditan, The serum concentration of Relugolix can be increased when it is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Relugolix can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Relugolix.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Relugolix.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Relugolix.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Relugolix.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Relugolix.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Relugolix.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Relugolix.]
[H02CA02, osilodrostat, The metabolism of Relugolix can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Relugolix can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Relugolix can be decreased when combined with Dutasteride.]
[L01EE04, selumetinib, The serum concentration of Relugolix can be increased when it is combined with Selumetinib.]
[C01BD07, dronedarone, The serum concentration of Relugolix can be increased when it is combined with Dronedarone.]
[S03AA08, chloramphenicol, The metabolism of Relugolix can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Relugolix.]
[L01EH03, tucatinib, The serum concentration of Relugolix can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Relugolix can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Relugolix can be increased when combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Relugolix can be increased when it is combined with Ripretinib.]
[C08CA17, levamlodipine, The metabolism of Relugolix can be decreased when combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Relugolix.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Relugolix.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Relugolix.]
[L04AC19, satralizumab, The serum concentration of Relugolix can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Relugolix can be increased when it is combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Relugolix.]
[B06AC06, berotralstat, The metabolism of Relugolix can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Relugolix can be increased when it is combined with Lonafarnib.]
[S01AA13, fusidic acid, The metabolism of Relugolix can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Pipemidic acid.]
[L04AD03, voclosporin, The serum concentration of Relugolix can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Relugolix can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Relugolix can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Relugolix can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Relugolix.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Relugolix.]
[G04CB01, finasteride, The metabolism of Relugolix can be decreased when combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Relugolix.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Relugolix.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Relugolix.]
[L01EK03, tivozanib, The serum concentration of Relugolix can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Relugolix.]
[A02BA01, cimetidine, The metabolism of Relugolix can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Relugolix can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Relugolix can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Citalopram.]
[V09IX16, piflufolastat F-18, Relugolix may decrease effectiveness of Piflufolastat F 18 as a diagnostic agent.]
[L04AA48, belumosudil, The serum concentration of Relugolix can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Relugolix.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Relugolix.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Clemastine.]
[J01FF01, clindamycin, The metabolism of Relugolix can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Relugolix can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Relugolix can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Relugolix can be increased when it is combined with Maribavir.]
[V09IX14, gallium GA-68 gozetotide, Relugolix may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent.]
[D11AH08, abrocitinib, The serum concentration of Relugolix can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Relugolix can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Relugolix can be increased when it is combined with Mitapivat.]
[L01EJ03, pacritinib, The serum concentration of Relugolix can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Relugolix can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Clomipramine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Relugolix.]
[C01EB24, mavacamten, The serum concentration of Relugolix can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Relugolix can be decreased when combined with Vonoprazan.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Relugolix can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Relugolix.]
[A10BK06, sotagliflozin, The serum concentration of Relugolix can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Relugolix can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Relugolix can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The serum concentration of Relugolix can be increased when it is combined with Colchicine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Relugolix.]
[A10BX03, nateglinide, The metabolism of Relugolix can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Relugolix can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Desloratadine.]
[J02AC02, itraconazole, The serum concentration of Relugolix can be increased when it is combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Relugolix can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Relugolix.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Relugolix.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Relugolix.]
[S01BA03, cortisone, The metabolism of Relugolix can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Lomefloxacin.]
[H02AB15, meprednisone, The metabolism of Relugolix can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Relugolix.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Relugolix.]
[C03DA04, eplerenone, The metabolism of Relugolix can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Melperone.]
[J05AF07, tenofovir disoproxil, The serum concentration of Relugolix can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Relugolix.]
[S01XA18, cyclosporine, The serum concentration of Relugolix can be increased when it is combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Relugolix can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Relugolix.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Relugolix.]
[C10AA07, rosuvastatin, The metabolism of Relugolix can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The serum concentration of Relugolix can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Relugolix can be increased when it is combined with Vardenafil.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Relugolix.]
[G03XA01, danazol, The metabolism of Relugolix can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Relugolix can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Relugolix can be increased when combined with Daunorubicin.]
[N06AX06, nefazodone, The metabolism of Relugolix can be decreased when combined with Nefazodone.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Relugolix.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Relugolix.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The metabolism of Relugolix can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Relugolix can be decreased when it is combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Relugolix can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Relugolix can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Relugolix can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Relugolix can be decreased when combined with Dextromethorphan.]
[B01AC04, clopidogrel, The metabolism of Relugolix can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Relugolix can be decreased when combined with Diazepam.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Relugolix.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Relugolix.]
[L01DC04, ixabepilone, The serum concentration of Relugolix can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Relugolix.]
[C08CA03, isradipine, The metabolism of Relugolix can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Relugolix can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Relugolix.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Relugolix.]
[J05AE08, atazanavir, The metabolism of Relugolix can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Relugolix.]
[C08DB01, diltiazem, The metabolism of Relugolix can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Dimenhydrinate.]
[C05CA03, diosmin, The serum concentration of Relugolix can be increased when it is combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Relugolix.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Relugolix.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Relugolix.]
[S02AA12, rifamycin SV, The serum concentration of Relugolix can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Relugolix can be decreased when it is combined with Rifapentine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Relugolix.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Relugolix.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Relugolix.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Relugolix.]
[A04AD12, aprepitant, The metabolism of Relugolix can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Relugolix.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Relugolix.]
[G04BE08, tadalafil, The metabolism of Relugolix can be decreased when combined with Tadalafil.]
[C02KX02, ambrisentan, The serum concentration of Relugolix can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Relugolix can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Relugolix.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Relugolix.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Relugolix.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Relugolix.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Relugolix.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Droperidol.]
[C10AA01, simvastatin, The serum concentration of Relugolix can be increased when it is combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Relugolix.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Temafloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Terodiline.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Relugolix.]
[L02BA02, toremifene, The serum concentration of Relugolix can be increased when it is combined with Toremifene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Relugolix.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Relugolix.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Relugolix.]
[C08CA12, mepirodipine, The metabolism of Relugolix can be decreased when combined with Barnidipine.]
[N03AX15, zonisamide, The serum concentration of Relugolix can be increased when it is combined with Zonisamide.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Relugolix.]
[N02CA02, ergotamine, The metabolism of Relugolix can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Relugolix can be increased when it is combined with Erythromycin.]
[R03BA09, fluticasone furoate, The metabolism of Relugolix can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Relugolix can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Relugolix can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Relugolix can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Relugolix.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Relugolix.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Relugolix.]
[L04AD02, tacrolimus, The serum concentration of Relugolix can be increased when it is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Relugolix.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Relugolix.]
[R06AX12, terfenadine, The metabolism of Relugolix can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Relugolix can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Relugolix.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Relugolix can be increased when it is combined with Pravastatin.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Relugolix.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Relugolix.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fendiline.]
[N02AB03, fentanyl, The metabolism of Relugolix can be decreased when combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Relugolix.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Flecainide.]
[J02AC01, fluconazole, The serum concentration of Relugolix can be increased when it is combined with Fluconazole.]
[D07AC08, fluocinonide, The metabolism of Relugolix can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Relugolix can be increased when combined with Fluocortolone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fluorouracil.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Relugolix can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Relugolix.]
[J05AE10, darunavir, The metabolism of Relugolix can be decreased when combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Relugolix.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Relugolix.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Relugolix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Relugolix.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Relugolix.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Relugolix.]
[N01AH02, alfentanil, The metabolism of Relugolix can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Relugolix can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Relugolix can be decreased when combined with Glyburide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Dofetilide.]
[L01EX02, sorafenib, The serum concentration of Relugolix can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Relugolix.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Relugolix.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Relugolix.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Relugolix can be decreased when combined with Irinotecan.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Relugolix.]
[J05AG01, nevirapine, The metabolism of Relugolix can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Relugolix can be decreased when combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Relugolix.]
[S02BA01, hydrocortisone, The metabolism of Relugolix can be decreased when combined with Hydrocortisone.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Relugolix.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Relugolix.]
[S01BA13, rimexolone, The serum concentration of Relugolix can be decreased when it is combined with Rimexolone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Relugolix.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Relugolix.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Relugolix.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Relugolix.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Relugolix.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Relugolix.]
[N06AX17, milnacipran, The metabolism of Relugolix can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The serum concentration of Relugolix can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Relugolix can be decreased when combined with Alprazolam.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Relugolix.]
[C10AA06, cerivastatin, The metabolism of Relugolix can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Anagrelide.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Relugolix.]
[J04AC01, isoniazid, The metabolism of Relugolix can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The metabolism of Relugolix can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The serum concentration of Relugolix can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Relugolix can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Relugolix.]
[L04AA24, abatacept, The metabolism of Relugolix can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Relugolix.]
[G03AD01, levonorgestrel, The metabolism of Relugolix can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Relugolix can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Relugolix can be increased when combined with Armodafinil.]
[A07DA03, loperamide, The serum concentration of Relugolix can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Relugolix can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Relugolix can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Relugolix can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The serum concentration of Relugolix can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Relugolix can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Relugolix.]
[P01BC02, mefloquine, The serum concentration of Relugolix can be increased when it is combined with Mefloquine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Mesoridazine.]
[N05AX13, paliperidone, The serum concentration of Relugolix can be increased when it is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Methadone.]
[H03BB02, methimazole, The metabolism of Relugolix can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Relugolix.]
[V04CG05, methylene blue, The serum concentration of Relugolix can be increased when it is combined with Methylene blue.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Relugolix.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Relugolix.]
[S02AA13, miconazole, The metabolism of Relugolix can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The metabolism of Relugolix can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Relugolix can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The serum concentration of Relugolix can be decreased when it is combined with Mitotane.]
[C01BD01, amiodarone, The serum concentration of Relugolix can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Relugolix can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Relugolix can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Relugolix.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Relugolix.]
[G04CA04, silodosin, The serum concentration of Relugolix can be increased when it is combined with Silodosin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Relugolix.]
[N03AB05, fosphenytoin, The serum concentration of Relugolix can be decreased when it is combined with Fosphenytoin.]
[V03AB15, naloxone, The metabolism of Relugolix can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Relugolix can be increased when combined with Anakinra.]
[A10BG01, troglitazone, The metabolism of Relugolix can be decreased when combined with Troglitazone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Relugolix.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Relugolix can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Relugolix can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Nimodipine.]
[C08CA07, nisoldipine, The metabolism of Relugolix can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Relugolix.]
[N05CF03, zaleplon, The metabolism of Relugolix can be decreased when combined with Zaleplon.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Relugolix.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Relugolix.]
[A16AX07, sapropterin, The serum concentration of Relugolix can be increased when it is combined with Sapropterin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Relugolix.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Relugolix can be increased when combined with Rilonacept.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxolinic acid.]
[N02AA05, oxycodone, The metabolism of Relugolix can be decreased when combined with Oxycodone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Relugolix.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Papaverine.]
[H02AB05, paramethasone, The metabolism of Relugolix can be increased when combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Relugolix.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Penfluridol.]
[N05CA01, pentobarbital, The serum concentration of Relugolix can be decreased when it is combined with Pentobarbital.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Relugolix.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Relugolix.]
[N03AA02, phenobarbital, The serum concentration of Relugolix can be decreased when it is combined with Phenobarbital.]
[N03AB02, phenytoin, The serum concentration of Relugolix can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Relugolix can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Levofloxacin.]
[C08CX01, mibefradil, The serum concentration of Relugolix can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Relugolix.]
[C10AA05, atorvastatin, The metabolism of Relugolix can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The serum concentration of Relugolix can be increased when it is combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Relugolix can be decreased when combined with Delavirdine.]
[L04AC08, canakinumab, The metabolism of Relugolix can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Relugolix can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Relugolix can be decreased when combined with Saxagliptin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Relugolix can be decreased when combined with Praziquantel.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Relugolix can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Relugolix can be decreased when it is combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Procainamide.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Relugolix can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Relugolix.]
[C01BC03, propafenone, The serum concentration of Relugolix can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Relugolix can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Relugolix.]
[C07AA05, propranolol, The metabolism of Relugolix can be decreased when combined with Propranolol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Relugolix.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Relugolix.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Relugolix.]
[P01AX05, quinacrine, The metabolism of Relugolix can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Relugolix can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Relugolix can be increased when it is combined with Quinine.]
[C02AA02, reserpine, The serum concentration of Relugolix can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Relugolix can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Roxithromycin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Relugolix.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Relugolix can be increased when it is combined with Technetium Tc-99m sestamibi.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Relugolix.]
